SM
EPZM

Sabby Management’s Epizyme, Inc EPZM Stock Holding History

Sabby Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-154
Closed -$479K – 310
2014
Q2 		$479K Buy
+154
New +$3.63K 0.02% 194

Other funds holding EPZM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Sabby Management's EPZM Position: Q2 2015 in Review

Sabby Management sold out of Epizyme, Inc (EPZM) in Q2 2015, closing a stake of 111,536 shares — an estimated $2.1M sold.

Sabby Management first reported a position in EPZM in Q1 2014 and held it in 3 quarters. The position peaked at $3.44M in Q1 2014. 95 funds tracked by Wall St. Rank hold EPZM as of Q2 2015.

  • Sabby Management reported no remaining Epizyme, Inc position as of Q2 2015 after selling out during the quarter.
  • Sabby Management sold 111,536 Epizyme, Inc shares in Q2 2015, an estimated $2.1M.
  • Sabby Management first reported a position in Epizyme, Inc in Q1 2014 and held it in 3 quarters.
  • Sabby Management's Epizyme, Inc position peaked at $3.44M in Q1 2014.
  • 95 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2015.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.